Engene Holdings Inc. (ENGN)
NASDAQ:ENGN
Want to see ENGN full AI Analyst Report?
ENGN Stock Chart & Stats
$8.07
$0.17(2.19%)
At close: 4:00 PM EST
$8.07
$0.17(2.19%)
Day’s Range― - ―
52-Week Range$1.40 - $12.25
Previous CloseN/A
Volume16.79K
Average Volume (3M)2.87M
Market Cap
$107.18M
Enterprise Value$91.56M
Total Cash (Recent Filing)$275.95M
Total Debt (Recent Filing)$33.46M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Jun 12, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding66,989,460
10 Day Avg. Volume849,851
30 Day Avg. Volume2,871,838
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-484.45
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$3.33Price Target Upside-58.69% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA materially improved equity base of $281.5M and very low reported debt give enGene substantial financial flexibility relative to peers. This reduces short-term solvency risk, supports continued clinical investment and regulatory interactions, and lengthens runway versus highly leveraged biotech peers.
Regulatory Designations & FDA EngagementRMAT and Fast Track plus inclusion in an FDA CMC pilot represent durable process advantages: they can speed reviews, enable earlier regulator feedback on manufacturing, and materially de-risk the pathway to a BLA. These designations improve odds of timely submission and potential accelerated development.
Governance ContinuityStrong shareholder support for the board and auditor strengthens governance continuity, reducing execution risk during late-stage development. Stable leadership and oversight support fundraising, regulatory interactions and strategic partnerships needed to transition from development to potential commercialization.
Bears Say
High Cash BurnPersistent and worsening operating cash outflows create a structural funding requirement. Continued negative OCF/FCF implies reliance on external capital to complete pivotal programs; frequent financings risk dilution and can limit strategic flexibility, making successful capital raises a critical ongoing constraint.
Pre-revenue & Earnings VolatilityWith no product revenue, financial performance depends on sporadic non-operating items and milestone timing, not commercial sales. Large swings in net income and negative ROE reflect weak earnings quality and a binary business outcome tied to trial and approval success rather than stable cash generation.
Durability Concerns In Pivotal DataInterim LEGEND durability metrics and weaker responses in recent enrollees suggest potential label, approval or commercial adoption risks. Less durable benefit could require additional studies, narrower indications, or hamper reimbursement and uptake, materially affecting long-term revenue prospects.
enGene Holdings News
ENGN FAQ
What was Engene Holdings Inc.’s price range in the past 12 months?
Engene Holdings Inc. lowest stock price was $1.40 and its highest was $12.25 in the past 12 months.
What is Engene Holdings Inc.’s market cap?
Engene Holdings Inc.’s market cap is $107.18M.
When is Engene Holdings Inc.’s upcoming earnings report date?
Engene Holdings Inc.’s upcoming earnings report date is Jun 12, 2026 which is today.
How were Engene Holdings Inc.’s earnings last quarter?
Engene Holdings Inc. released its earnings results on Mar 09, 2026. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.12.
Is Engene Holdings Inc. overvalued?
According to Wall Street analysts Engene Holdings Inc.’s price is currently Overvalued.
Does Engene Holdings Inc. pay dividends?
Engene Holdings Inc. pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on Engene Holdings Inc. dividends here
What is Engene Holdings Inc.’s EPS estimate?
Engene Holdings Inc.’s EPS estimate is -0.47.
How many shares outstanding does Engene Holdings Inc. have?
Engene Holdings Inc. has 66,989,460 shares outstanding.
What happened to Engene Holdings Inc.’s price movement after its last earnings report?
Engene Holdings Inc. reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went down -18.779%.
Which hedge fund is a major shareholder of Engene Holdings Inc.?
Currently, no hedge funds are holding shares in ENGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
enGene Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.33 (-58.69% Downside)
$3.33 (-58.69% Downside)
Blogger Sentiment
Bullish
ENGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.15%
12-Months-Change
Fundamentals
Return on Equity
-55.83%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Engene Holdings Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$3.33
▼(-58.69% Downside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
4.47%
Insiders
0.73% Mutual Funds
― Other Institutional Investors
94.75% Public Companies and
Individual Investors